Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371748 · ClinicalTrials.gov registry record · Phase 3

A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels

A Phase 3 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
261
Enrollment target

NCT00371748 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 261 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371748, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
261 participants
Enrollment target

Study Summary

TAXUS ATLAS Small Vessel is a global, multi-center, single-arm, trial of patients with coronary arteries less than 2.5 mm in diameter who are treated with the TAXUS Liberté stent versus an historical TAXUS Express control derived from a subset of lesion-matched TAXUS V patients treated with a 2.25 mm stent. The objective of the study is to evaluate clinical and angiographic outcomes of TAXUS Liberté-SR 2.25 mm stent in de novo lesions. The hypothesis is that the TAXUS Liberté-SR stent has non-inferior safety and efficacy to the TAXUS Express-SR stent in the treatment of de novo lesions in small coronary vessels.

Interventions

  • DEVICE TAXUS Liberté-SR
  • DEVICE TAXUS™ Express2
  • DEVICE Express2

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2005-02
Est. Completion 2011-04
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00371748

The ClinicalTrials.gov registry entry for NCT00371748 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which TAXUS Liberté-SR is the first listed.

NCT00371748 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00371748 about?

NCT00371748 is a clinical study titled "A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels". TAXUS ATLAS Small Vessel is a global, multi-center, single-arm, trial of patients with coronary arteries less than 2.5 mm in diameter who are treated with the TAXUS Liberté stent versus an historical TAXUS Express control derived from a subset of lesion-matched TAXUS V patients treated with a 2.25 m...

What is the current status of trial NCT00371748?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2005-02. Estimated completion is 2011-04.

What interventions are being tested in trial NCT00371748?

The interventions under investigation include: TAXUS Liberté-SR (DEVICE), TAXUS™ Express2 (DEVICE), Express2 (DEVICE).

Who is sponsoring clinical trial NCT00371748?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.